rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2016-12-2-191-195rpcardio-1238Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION?ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ И ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА: КАК СОЧЕТАТЬ АНТИАГРЕГАНТНУЮ И АНТИКОАГУЛЯНТНУЮ ТЕРАПИЮ В ЗАВИСИМОСТИ ОТ КЛИНИЧЕСКОЙ СИТУАЦИИ?НапалковД. А.NapalkovD. A.

Напалков Дмитрий Александрович – доктор медицинских наук, профессор кафедры факультетской терапии №1 лечебного факультета Первого МГМУ имени И.М. Сеченова

dminap@mail.ruСоколоваА. А.SokolovaA. A.

Соколова Анастасия Андреевна – научный сотрудник научноисследовательского отдела аритмологии научноисследовательского центра Первого МГМУ имени И.М. Сеченова 

dminap@mail.ruРодионовА. В.RodionovA. V.

Родионов Антон Владимирович – кандидат медицинских наук,  доцент кафедры факультетской терапии №1 лечебного факультета Первого МГМУ имени И.М. Сеченова

dminap@mail.ruПервый Московский государственный медицинский университет имени И. М. Сеченова, МоскваРоссияI.M. Sechenov First Moscow State Medical University, MoscowRussian Federation201605052016122191195Copyright © Napalkov D.A., Sokolova A.A., Rodionov A.V., 20162016Напалков Д.А., Соколова А.А., Родионов А.В.Napalkov D.A., Sokolova A.A., Rodionov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1238

Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic events) are discussed. The authors briefly present subanalysis of ARISTOTLE study, which compares the efficacy and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic heart disease.

В статье рассматриваются современные европейские подходы к ведению пациентов с фибрилляцией предсердий (ФП), перенесших острый коронарный синдром и/или чрескожные интервенционные вмешательства на коронарных артериях. Обсуждаются особенности антитромботической терапии в ранний (стационарный) и в отсроченный период (до 1 года после ишемического события). Авторы также кратко представляют субанализ исследования ARISTOTLE, в котором сравниваются эффективность и безопасность апиксабана в сравнении с варфарином у пациентов с ФП, имеющих в анамнезе ишемическую болезнь сердца.

фибрилляция предсердийишемическая болезнь сердцаострый коронарный синдромварфаринпрямые пероральные антикоагулянтыапиксабанatrial fibrillationischemic heart diseaseacute coronary syndromewarfarindirect oral anticoagulantapixabanReferencesThompson PL, Verheugt WAV. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther 2014; 36: 1176-81.Thompson PL, Verheugt WAV. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther 2014; 36: 1176-81.Antithrombotic Triallist’s Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.Antithrombotic Triallist’s Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC Guidelines on the management of the stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC Guidelines on the management of the stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.Steg PG, James SK, Atar D et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.Steg PG, James SK, Atar D et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention; a randomized controlled trial. JAMA 2002; 288: 2411-20.Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention; a randomized controlled trial. JAMA 2002; 288: 2411-20.Chen ZM, Jiang LX, Chen YP et al. Additon of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21.Chen ZM, Jiang LX, Chen YP et al. Additon of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21.Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet 2013; 381: 1107-15.Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet 2013; 381: 1107-15.Fox KA. Dual or single antiplatelet therapy with anticoagulation? Lancet 2013; 381: 1080-81.Fox KA. Dual or single antiplatelet therapy with anticoagulation? Lancet 2013; 381: 1080-81.Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; doi: 10.1093/europace/euv309.Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; doi: 10.1093/europace/euv309.Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577-1585.Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577-1585.Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol 2013; 170: 215-220.Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol 2013; 170: 215-220.Rao MP, Pokorney SD, Granger CB. Atrial fibrillation: a review of recent studies with the focus on those from the Duke clinical research institute. Scientifica (Cairo) 2014; 2014:901586.Rao MP, Pokorney SD, Granger CB. Atrial fibrillation: a review of recent studies with the focus on those from the Duke clinical research institute. Scientifica (Cairo) 2014; 2014:901586.

The authors declare that there are no conflicts of interest present.